{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:58:18Z","timestamp":1791863898464,"version":"4.3.4"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T00:00:00Z","timestamp":1140566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> In view of the association of hyperprolactinaemia with insulin resistance, we hypothesized that patients with hyperprolactinaemia may present increased cardiovascular risk markers.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Descriptive clinical trial.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Serum glucose, insulin, insulin resistance, lipids, high sensitivity C\u2010reactive protein (hsCRP), interleukin (IL)\u20106, tumour necrosis factor (TNF)\u2010\u03b1 and soluble E\u2010selectin (sELAM\u20101) serum levels were determined in 15 patients with hyperprolactinaemia at baseline (compared with 20 healthy subjects) and after 12\u00a0weeks of cabergoline therapy (0\u00b75\u20131\u00a0mg twice per week). We also measured mononuclear cell NF\u2010\u03baB activation and TNF\u2010\u03b1 production in a subset of subjects.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Serum levels of prolactin (PRL), insulin, insulin resistance (HOMA\u2010IR) index and hsCRP were significantly higher in patients than in control subjects. Markers of mononuclear cell activation did not differ between the groups. Hyperprolactinaemia, BMI and age were predictors of hsCRP. BMI was the only predictor of HOMA\u2010IR. Cabergoline therapy significantly reduced serum PRL, insulin, hsCRP and sELAM\u20101 levels.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> These data suggest that hyperprolactinaemia is associated with insulin resistance related to increased BMI and low\u2010grade inflammation independently of BMI. Short\u2010term cabergoline therapy can reduce the inflammatory markers.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2006.02469.x","type":"journal-article","created":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T09:04:56Z","timestamp":1140599096000},"page":"366-370","source":"Crossref","is-referenced-by-count":117,"title":["The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy"],"prefix":"10.1111","volume":"64","author":[{"given":"Omar","family":"Serri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Claude","family":"Mamputu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Claude","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Maingrette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Renier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,2,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)59165-1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)49291-5"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-51-2-242"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF00273860","article-title":"Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo","volume":"28","author":"Schernthaner G.","year":"1985","journal-title":"Diabetologia"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00403.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490187"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/rp.57.1.435"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4781(91)90032-H"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704033361401"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000052939.59093.45"},{"key":"e_1_2_6_15_2","first-page":"199","article-title":"Regulation of the human C\u2010reactive protein gene, a major marker of inflammation and cancer","volume":"7","author":"Toniatti C.","year":"1990","journal-title":"Molecular and Biological Medicine"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.147.4.1261","article-title":"Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C\u2010reactive protein in Hep 3B cells","volume":"147","author":"Ganapathi M.K.","year":"1991","journal-title":"Journal of Immunology"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00490.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar576"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.1.58"},{"key":"e_1_2_6_20_2","first-page":"499","article-title":"Endothelial nuclear factor\u2010kappa B and the initiation of the atherosclerotic lesion","volume":"68","author":"Collins T.","year":"1993","journal-title":"Laboratory Investigations"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2003.10.013"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.1.42"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.4.972"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.8.1672"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.46"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2006.02469.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2006.02469.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T19:46:20Z","timestamp":1697226380000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2006.02469.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,22]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1365-2265.2006.02469.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02469.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,22]]}}}